MEDIUM confidence: 100% data completeness, but the composite (54) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-08-23.
Fewer than 3 analysts refreshed a price target in the last month, so no revision can be computed. Prior quarter: $91 avg across 3 analysts.
Buy-rated share 70% → 73% over ~3 months (+3pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Oct 2026 | $1.20 | $1.34 | +11.7% |
| Jul 2026 | $1.04 | $1.13 | +8.7% |
| Apr 2026 | $1.04 | $0.99 | -4.8% |
| Feb 2026 | $1.40 | $1.44 | +2.9% |
| Oct 2025 | $1.05 | $1.07 | +1.9% |
| Jul 2025 | $0.92 | $1.06 | +15.5% |
| Apr 2025 | $0.91 | $1.01 | +10.5% |
| Feb 2025 | $1.26 | $1.45 | +15.1% |
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $17.6B— | $18.3B+4.3% | $19.6B+6.6% | $19.7B+0.6% | $20.6B+4.8% |
| EPS (dil.) | $4.90— | $4.22-13.9% | $3.02-28.4% | $4.34+43.7% | $4.55+4.8% |
| Free Cash Flow | $1.4B— | $1.8B+32.7% | $1.7B-4.9% | $1.6B-9.6% | $1.5B-2.8% |
| Gross Margin | 40.8% | 39.1%-1.7pp | 40.5%+1.4pp | 41.7%+1.2pp | 40.0%-1.7pp |
| Operating Margin | 15.9% | 13.8%-2.1pp | 12.5%-1.3pp | 13.3%+0.9pp | 13.4%+0.0pp |
| Net Margin | 12.8% | 10.4%-2.3pp | 8.0%-2.4pp | 10.1%+2.1pp | 10.1%-0.0pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of 5.3%/yr (revenue basis).
Base free cash flow $1.6B (avg FY2023–FY2025; latest year $1.5B) · equity value $34.5B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
Net insider $5.9M over 180 days (5 open-market buys, 0 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
The QScore of 54 indicates a neutral outlook for GEHC, with the long-term and short-term scores closely aligned. The stock scores relatively high on risk factors, driven by its low beta and moderate volatility, but is held back by its growth metrics, including revenue and EPS growth of 4.8% and 4.3%, respectively. The stock trades at a P/E of 19.8, which is not overly demanding, and exhibits strong profitability with an ROE of 16.1%, but its momentum is mixed, with a 12-month return of -1.5% and a recent 3-month return of 9.4%.